Suppr超能文献

心脏再同步治疗对终末期依赖血管活性药物的心衰患者的疗效

Efficacy of cardiac resynchronisation therapy in the treatment of end-stage inotrope-dependent heart failure patients.

作者信息

Sokal Adam, Jędrzejczyk Ewa, Lenarczyk Radosław, Pluta Sławomir, Kowalski Oskar, Pruszkowska Patrycja, Mazurek Michał, Swiątkowski Andrzej, Kalarus Zbigniew

机构信息

Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Centre for Heart Diseases, Zabrze, Poland.

出版信息

Kardiol Pol. 2014;72(9):777-82. doi: 10.5603/KP.a2014.0090. Epub 2014 May 20.

Abstract

BACKGROUND AND AIM

Currently, cardiac resynchronisation therapy (CRT) is recommended only for New York Heart Association (NYHA) class IV ambulatory patients. However, some recent reports have suggested that CRT could also be beneficial for end-stage inotrope-dependent heart failure (HF) NYHA class IV patients. In this report, we summarise the results of CRT implantation in a group of 11 HF inotrope-dependent patients who were not candidates for urgent orthotopic heart transplantation (OHT).

METHODS AND RESULTS

Between August 2006 and June 2011, 11 end-stage inotrope-dependent HF patients with wide QRS complex, ineligible for urgent OHT, were implanted with CRT in the Silesian Centre for Heart Diseases in Zabrze. Dependence on inotropic therapy was defined as an inability to stop the infusion of the drug without the occurrence of hypotension, oligooranuria and/or hypoxaemia. All patients were successfully implanted with CRT and subsequently weaned from inotropes in a median time of two (1-17) days. Mean QRS duration shortened from 190 ± 34 ms at baseline to 142 ± 25 ms (p < 0.001) after the procedure. Average left ventricular ejection fraction increased from 19 ± 4% to 25 ± 4% (p < 0.001). All patients were discharged from hospital. Median hospital stay after the procedure was ten (5-56) days. During the median follow-upof 1,212 (182-2,048) days, four patients died (one due to arrhythmic storm, three others due to progressive pump failure). During that period, 57 adequate device interventions occurred in three patients, including 52 therapies in one fatal case.

CONCLUSIONS

CRT can be an alternative for end-stage inotrope-dependent HF patients with wide QRS who are ineligible for urgent heart transplantation.

摘要

背景与目的

目前,心脏再同步治疗(CRT)仅推荐用于纽约心脏协会(NYHA)IV级的非卧床患者。然而,最近一些报告表明,CRT对NYHA IV级的终末期依赖血管活性药物的心衰(HF)患者也可能有益。在本报告中,我们总结了一组11例依赖血管活性药物的心衰患者植入CRT的结果,这些患者并非紧急原位心脏移植(OHT)的候选者。

方法与结果

2006年8月至2011年6月期间,11例终末期依赖血管活性药物、QRS波增宽且不符合紧急OHT标准的HF患者在扎布热的西里西亚心脏病中心植入了CRT。对血管活性药物治疗的依赖定义为在不发生低血压、少尿和/或低氧血症的情况下无法停止药物输注。所有患者均成功植入CRT,随后在中位时间为2(1 - 17)天内停用血管活性药物。术后平均QRS时限从基线时的190±34毫秒缩短至142±25毫秒(p < 0.001)。平均左心室射血分数从19±4%增加到25±4%(p < 0.001)。所有患者均出院。术后中位住院时间为10(5 - 56)天。在中位随访1212(182 - 2048)天期间,4例患者死亡(1例死于心律失常风暴,另外3例死于进行性泵衰竭)。在此期间,3例患者发生了57次适当的设备干预,其中1例致命病例进行了52次治疗。

结论

对于不符合紧急心脏移植标准、QRS波增宽的终末期依赖血管活性药物的心衰患者,CRT可以作为一种替代治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验